|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPLP2 |
Gene summary for RPLP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPLP2 | Gene ID | 6181 |
| Gene name | ribosomal protein lateral stalk subunit P2 | |
| Gene Alias | D11S2243E | |
| Cytomap | 11p15.5 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | A0A024RCA7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6181 | RPLP2 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 8.39e-104 | -1.03e+00 | 0.1604 |
| 6181 | RPLP2 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 2.12e-72 | -5.28e-01 | 0.1621 |
| 6181 | RPLP2 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 6.73e-73 | -7.79e-01 | 0.1619 |
| 6181 | RPLP2 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 4.79e-51 | -6.64e-01 | 0.159 |
| 6181 | RPLP2 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 5.57e-90 | -8.43e-01 | 0.1602 |
| 6181 | RPLP2 | GSM5353228_PA_PR5199-640K_Pool_1_3_S108_L004 | Human | Prostate | Tumor | 2.06e-15 | -8.24e-01 | 0.1537 |
| 6181 | RPLP2 | GSM5353232_PA_PR5249_T1_S3_L001 | Human | Prostate | Tumor | 8.97e-22 | -7.57e-01 | 0.1439 |
| 6181 | RPLP2 | GSM5353236_PA_PR5251_T1_S7_L001 | Human | Prostate | Tumor | 1.28e-83 | -1.12e+00 | 0.1608 |
| 6181 | RPLP2 | GSM5353237_PA_PR5251_T2_S8_L001 | Human | Prostate | Tumor | 8.97e-68 | -9.45e-01 | 0.1622 |
| 6181 | RPLP2 | GSM5353240_PA_PR5254_T1_S15_L001 | Human | Prostate | Tumor | 2.25e-94 | -6.54e-01 | 0.1575 |
| 6181 | RPLP2 | GSM5353243_PA_PR5261_T1_S23_L002 | Human | Prostate | Tumor | 4.72e-102 | -9.67e-01 | 0.1545 |
| 6181 | RPLP2 | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 1.33e-104 | -1.22e+00 | 0.1569 |
| 6181 | RPLP2 | GSM5353247_PA_PR5269_3_S27_L002 | Human | Prostate | Tumor | 6.12e-24 | -1.23e+00 | 0.1532 |
| 6181 | RPLP2 | GSM5353248_PA_PR5269_4_S28_L002 | Human | Prostate | Tumor | 5.44e-30 | -9.76e-01 | 0.1541 |
| 6181 | RPLP2 | P1_S1_AK | Human | Skin | AK | 5.34e-43 | -1.66e-01 | -0.3399 |
| 6181 | RPLP2 | P2_S3_AK | Human | Skin | AK | 1.15e-41 | -1.70e-01 | -0.3287 |
| 6181 | RPLP2 | P2_S4_SCCIS | Human | Skin | SCCIS | 1.14e-27 | -1.79e-01 | -0.3043 |
| 6181 | RPLP2 | P3_S6_AK | Human | Skin | AK | 2.62e-30 | -2.33e-01 | -0.3256 |
| 6181 | RPLP2 | P4_S8_cSCC | Human | Skin | cSCC | 1.11e-09 | -5.34e-02 | -0.3095 |
| 6181 | RPLP2 | P5_S10_cSCC | Human | Skin | cSCC | 1.78e-58 | -2.06e-01 | -0.299 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
| GO:00064147 | Breast | Precancer | translational elongation | 10/1080 | 55/18723 | 1.06e-03 | 1.18e-02 | 10 |
| GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
| GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
| GO:000641413 | Breast | DCIS | translational elongation | 10/1390 | 55/18723 | 6.66e-03 | 4.62e-02 | 10 |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:00064148 | Cervix | HSIL_HPV | translational elongation | 7/737 | 55/18723 | 5.59e-03 | 4.47e-02 | 7 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:0006414 | Colorectum | AD | translational elongation | 21/3918 | 55/18723 | 2.53e-03 | 1.93e-02 | 21 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00064141 | Colorectum | SER | translational elongation | 17/2897 | 55/18723 | 3.00e-03 | 2.65e-02 | 17 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:00064142 | Colorectum | MSS | translational elongation | 19/3467 | 55/18723 | 3.47e-03 | 2.59e-02 | 19 |
| GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
| GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
| GO:00021815 | Colorectum | CRC | cytoplasmic translation | 70/2078 | 148/18723 | 1.53e-28 | 9.16e-25 | 70 |
| GO:00064143 | Colorectum | CRC | translational elongation | 14/2078 | 55/18723 | 2.21e-03 | 2.15e-02 | 14 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:00064149 | Endometrium | AEH | translational elongation | 13/2100 | 55/18723 | 6.76e-03 | 3.94e-02 | 13 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPLP2 | SNV | Missense_Mutation | c.274N>C | p.Glu92Gln | p.E92Q | P05387 | protein_coding | deleterious(0.01) | benign(0.299) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| RPLP2 | deletion | Frame_Shift_Del | novel | c.99delN | p.Ala34ArgfsTer13 | p.A34Rfs*13 | P05387 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| RPLP2 | SNV | Missense_Mutation | novel | c.286N>T | p.Asp96Tyr | p.D96Y | P05387 | protein_coding | deleterious(0) | possibly_damaging(0.659) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| RPLP2 | SNV | Missense_Mutation | novel | c.72N>T | p.Lys24Asn | p.K24N | P05387 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| RPLP2 | SNV | Missense_Mutation | novel | c.113G>T | p.Arg38Leu | p.R38L | P05387 | protein_coding | deleterious(0.03) | possibly_damaging(0.498) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RPLP2 | SNV | Missense_Mutation | novel | c.127N>T | p.Ile43Phe | p.I43F | P05387 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RPLP2 | SNV | Missense_Mutation | c.116N>G | p.Leu39Arg | p.L39R | P05387 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD | |
| RPLP2 | SNV | Missense_Mutation | novel | c.235N>C | p.Ser79Pro | p.S79P | P05387 | protein_coding | tolerated(0.31) | benign(0.005) | TCGA-67-6215-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| RPLP2 | SNV | Missense_Mutation | rs367815234 | c.203N>T | p.Gly68Val | p.G68V | P05387 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-P3-A6SX-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | unknown | CR |
| RPLP2 | SNV | Missense_Mutation | rs370189970 | c.232N>T | p.Gly78Cys | p.G78C | P05387 | protein_coding | tolerated(0.1) | probably_damaging(0.979) | TCGA-BR-A4QI-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |